Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Nine-Weeks Administration of Three Doses of SB-683699 in Subjects With Moderately to Severely Active Crohn's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Firategrast (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 22 May 2009 New trial record